Importantly, external validation in two independent cohorts of advanced HCC patients treated with PD-1/PD-L1 inhibitors demonstrated consistent predictive performance (AUROC  =  0.64-0.73), confirming the model's generalizability in nonsurgical and immunotherapy contexts. The gene discussed is CD274; the disease is hepatocellular carcinoma.